Q&A: Page 7
Exclusive interviews with industry leaders
-
Permission granted by Alan Millar.
How an open platform can shake up the drug development process
TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.
Kim Ribbink • April 28, 2022 -
iStock via Getty Images
Real-world data is making drug development more true to life
How RWD is moving from the background to the spotlight in pharma’s development process.
Kelly Bilodeau • April 26, 2022 -
iStock via Getty Images
How OliX Pharmaceuticals is riding the RNAi wave
While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.
Karissa Waddick and Taren Grom • April 25, 2022 -
Stock via Getty Images
The cannabis vanguard: A rare disease company looks to pioneer in the space
Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.
Jared Whitlock • April 21, 2022 -
iStock via Getty Images
A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'
Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.
Alexandra Pecci • April 21, 2022 -
Justin Sullivan / Staff via Getty Images
How pharma can up its social media game
Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities.
Karissa Waddick • April 18, 2022 -
Yongyuan via Getty Images
Biotech goes Hollywood
A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.
Taren Grom • April 13, 2022 -
Stock via Getty Images
Down but not out: How AVEO's CEO steered the company past an FDA rejection
Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.
Kim Ribbink • April 5, 2022 -
Real Chemistry/PharmaVoice
Lessons from improv: Shankar Narayanan’s ‘yes, and’ approach to healthcare leadership
Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.
Taren Grom • April 4, 2022 -
Stock via Getty Images
Time-saving tech lights Alcon's path into digital innovation
Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a North Star when developing digital tools.
Kim Ribbink • April 4, 2022 -
Sangamo Therapeutics
Sangamo has its finger on the next evolution of gene editing
Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.
Taren Grom • March 31, 2022 -
Stock via Getty Images
Rare Patient Voice's president is striving to create a five-star experience for patients
Successful clinical trial recruitment depends on listening to and empowering patients.
Kim Ribbink • March 23, 2022 -
Stock via Getty Images
Why Astellas is adopting a 'focus area approach' to partnerships
Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.
Kim Ribbink • March 22, 2022 -
Retrieved from PharmaVOICE on March 21, 2022
BioMarin’s new global head of advocacy is tackling the holy grail of patient engagement
In her new role, Dr. Roz is keeping her patient-first approach.
Taren Grom • March 21, 2022 -
Novartis' manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. Permission granted by Novartis.
How Novartis kept its supply chain intact during COVID-19
In an agile pivot, Amit Nastik led Novartis’ manufacturing operations through the pandemic without losing supply chain reliability.
Taren Grom • March 16, 2022 -
Image courtesy of Medigene.
Medigene's CEO on striking a collaboration deal with BioNTech
The two companies recently announced a $29 million collaboration.
Jared Whitlock • March 15, 2022 -
Permission granted by Sanjeev Luther.
Clearing hurdles in rare cancer drug development
Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.
Kim Ribbink • March 14, 2022 -
Stock via Getty Images
Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage
The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.
Taren Grom • March 14, 2022 -
Permission granted by Terry Weber
Biote CEO: Employers need to normalize women's health issues in the workforce
A survey by Biote reveals the impact of menopause on working women.
Robin Robinson • March 14, 2022 -
Image courtesy of Ultragenyx.
Ultragenyx's CEO on building a 'next-gen' rare disease company
How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.
Kim Ribbink • March 9, 2022 -
Permission granted by Ramona Sequeira.
Ramona Sequeira breaks PhRMA's glass ceiling
A few weeks ago, PhRMA, the industry’s largest trade group, announced that Sequeira has officially become chair of the organization’s board of directors. She is the first woman — and first woman of color — to take on the job.
Taren Grom • March 7, 2022 -
Permission granted by Andrew Hopkins.
Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started
The company’s CEO on the road ahead for AI capabilities in pharma.
Meagan Parrish • March 4, 2022 -
Stock via Getty Images
Candel's CEO looks to help ignite a new era of cancer treatments
Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.
Taren Grom • Feb. 28, 2022 -
Stock via Getty Images
Why plasma derived therapies have a unique edge in rare diseases
Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.
Kim Ribbink • Feb. 25, 2022 -
Stock via Getty Images
Winning buy-in from early stage biotech investors
The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.
Taren Grom • Feb. 11, 2022
Previous
